Department of Psychiatry
Penn Behavioral Health

Steven E. Arnold

faculty photo

Steven E. Arnold

Professor of Psychiatry
Associate Director, Institute on Aging, University of Pennsylvania, Philadelphia, PA
Associate Director, Alzheimer Disease Core Center, University of Pennsylvania
Director, Geriatric Psychiatry Section, University of Pennsylvania
Director, Penn Memory Center/Alzheimer's Disease Center Clincal Core, University of Pennsylvania, Philadelphia, PA
Department: Psychiatry
Graduate Group Affiliations

Contact information
Penn Memory Center
3615 Chestnut Street
or
2205 Translational Research Laboratories
123 South 31st Street
Philadelphia, PA 19104
Office: (215) 349-8225
Fax: (215) 349-8540
Lab: (215) 573-2840
Education:
M.D. (Medicine)
Boston University, 1983.
B.A. (Medical Science, Philosophy)
Boston University, Summa cum laude , 1983.
Post-Graduate Training
Intern in Internal Medicine, St. Luke's - Roosevelt Hospital Center, New York, NY, 1983-1984.
Resident in Psychiatry, New York State Psychiatric Institute / Columbia - Presbyterian Medical Center, New York, NY, 1984-1987.
Resident in Neurology, University of Iowa Hospitals and Clinics, Iowa City, IA, 1987-1990.
Postgraduate Associate, Neuroanatomy (with Gary W. Van Hoesen, Ph.D.), University of Iowa, 1987-1990.
Behavioral Neurology and Cognitive Neuroscience (with Antonio. R. Damasio, M.D., Ph.D.), University of Iowa Hospitals and Clinics, Iowa City, IA, 1989-1990.
Permanent link
 

Description of Research Expertise

schizophrenia; neuropsychiatry; cognition in aging and neurodegenerative dementias; clinicopathological correlation studies; postmortem research; cellular and molecular neuropathology; quantitative microscopy.

Description of Clinical Expertise

Evaluation, diagnosis and medical management of complex neuropsychiatric disorders; Alzheimer's disease and other neurodegenerative dementias;traumatic brain injury; cognitive, mood, and behavioral complications of neurological illness and injury.

Selected Publications

DeJesus-Cortes, H.J., Nogueras-Ortiz, C.J., Gearing, M., Arnold, S.E., Vega, I.E.: Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration. Neuroreport 23(16): 942-946, Nov 2012.

Naylor, M.D., Karlawish, J.H., Arnold, S.E., Khachaturian, A.S., Khachaturian, Z.S., Lee, V.M., Baumgart, M., Banerjee, S., Beck, C., Blennow, K., Brookmeyer, R., Brunden, K.R., Buckwalter, K.C., Comer,M., Covinsky, K., Feinberg, L.F., Frisoni, G., Green, C., Guimaraes, R.M., Gwyther, L.P., Hefti, F.F., Hutton, M., Kawas, C., Kent, D.M., Kuller, L., Langa, K.M., Mahley, R.W., Maslow, K., Masters, C.L., Meier, D.E., Neumann, P.J., Paul, S.M., Peterson, R.C., Sager, M.A., Sano, M., Schenk, D., Soares, H., Sperling, R.A., Stahl, S.M., vanDeerlin, V., Stern, Y., Weir, D., Wolk, D.A., Trojanowski, J.Q.: Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit. Alzheimers Dement 8(5): 445-52, Sep 2012.

Wolk, D.A., Zhang, Z., Boudhar, S., Clark, C.M., Pontecorvo, M.J., Arnold, S.E.: Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry 83(9): 923-6, Sep 2012.

Zhang, Q., Stafford, R.B., Wang, Z., Arnold, S.E., Wolk, D.A., Detre, J.A.: Microvascular Perfusion Based on Arterial Spin Labeled Perfusion MRI as a Measure of Vascular Risk in Alzheimer's Disease. J Alzheimers Dis. Aug 2012.

Hu, W.T., Holtzman, D.M., Fagan, A.M., Shaw, L.M., Perrin, R., Arnold, S.E., Grossman, M., Xiong, C., Craig-Schapiro, R., Clark, C.M., Pickering, E., Kuhn, M., Chen, Y., VanDeerlin, V.M., McClusky, L., Elman, L., Karlawish, J., Chen-Plotkin, A., Hurtig, H.I., Siderowf, A., Swenson, F., Lee, V.M., Morris, J.C., Trojanowski, J.Q., Soares, H.: Plasma multianalyte profiling in mild cognitive impairment and Alzheimer's disease. Neurology 79(9): 897-905, Aug 2012.

Irwin, D. J., McMillan, C.T., Toledo, J.B., Arnold, S.E., Shaw, L.M., Wang, L.S., VanDeerlin, V., Lee, V.M., Trojanowski, J.Q., Grossman, M.: Comparison of cerebrospinal fluid levels of tau and ab 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol 69(8): 1018-25, Aug 2012.

Toledo, J.B., Brettschneider, J., Grossman, M., Arnold, S.E., Hu, W.T., Xie, S.X., Lee, V.M., Shaw, L.M., Trojanowski, J.Q.: CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol. 124(1): 23-35, Jul 2012.

Farlow, M., Arnold, S.E., vanDyck, C.H., Aisen, P.S., Snider, B.J., Porsteinsson, A.P., Friedrich, S., Dean, R.A., Gonzales, C., Sethuraman, G., DeMattos, R.B., Mohs, R., Paul, S.M., Siemers, E.R.: Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 8(4): 261-71, Jul 2012.

Newberg, A.B., Arnold, S.E., Wintering, N., Rovner, B.W., Alavi, A.: Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med 53(6): 902-7, Jun 2012.

Talbot, K., Wang, H.Y., Kazi, H., Han, L.Y., Bakshi, K.P., Stucky, A., Fuino, R.L., Kawaguchi, K.R., Samoyedny, A.J., Wilson, R.S., Arvanitakis, Z., Schneider, J.A., Wolf, B.A., Bennett, D.A., Trojanowski, J.Q., Arnold, S.E.: Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122(4): 1316-38, Apr 2012.

back to top
Last updated: 01/24/2013
The Trustees of the University of Pennsylvania